April 16th 2024
Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Exploring Novel Combinations in Indolent Lymphomas
September 9th 2023Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.
Read More
Fixed-Duration Loncastuximab Tesirine May Be Beneficial Earlier on in R/R DLBCL Treatment
September 8th 2023Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.
Read More
FDA Gives Direction for BLA Resubmission of Denileukin Diftitox in CTCL
September 8th 2023Guidance from the FDA has provided a clear pathway and requested no additional efficacy or safety trials for the resubmission of the biologics license application for denileukin diftitox in cutaneous T-cell lymphoma.
Read More
Brentuximab Vedotin/Nivolumab Appears Well-Tolerated in Early-Stage cHL
June 13th 2023In part C of the phase 2 SGN35-027 trial evaluating brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine in patients with classical Hodgkin lymphoma, fewer than half of patients developed primarily low-grade peripheral neuropathy, and no cases of febrile neutropenia were observed.
Read More